Jyong Biotech (NASDAQ:MENS) Shares Down 19.3% – What’s Next?

Jyong Biotech Ltd. (NASDAQ:MENS)’s stock price dropped 19.3% during mid-day trading on Tuesday . The company traded as low as $18.01 and last traded at $18.07. Approximately 151,391 shares were traded during trading, a decline of 44% from the average daily volume of 269,087 shares. The stock had previously closed at $22.39.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Jyong Biotech in a research report on Wednesday, October 8th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, Jyong Biotech currently has an average rating of “Sell”.

Jyong Biotech Stock Performance

The firm has a 50-day simple moving average of $40.78.

Institutional Investors Weigh In On Jyong Biotech

An institutional investor recently bought a new position in Jyong Biotech stock. BNP Paribas Financial Markets purchased a new stake in Jyong Biotech Ltd. (NASDAQ:MENS) in the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,698 shares of the company’s stock, valued at approximately $67,000.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.